



**2023 COMPLEMENT UK TRAINING COURSE  
AND SYMPOSIUM**

**COMPLEMENT DIAGNOSTICS  
AND THERAPEUTICS**

**3-4 APRIL 2023**

CARDIFF UNIVERSITY

# POSTER PRESENTATIONS

---

- P-01** Lack of Complement Factor H contributes to endothelial cell injury in Shiga toxin Haemolytic Uraemic Syndrome, Emily Bowen
- P-02** Functional relevance of genetic associations at complement genes with risk of Alzheimer's disease, Samuel Keat
- P-03** Characterising complement in amyloid-beta plaques, Lewis Watkins
- P-04** GWAS of plasma complement protein levels reveals functional effects of Alzheimer's disease risk loci, Aurora Veteleanu
- P-05** Evaluation of minimal Factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury, Chloe Connolly
- P-06** Performance of a C2 Assay for use with EDTA plasma, Lithium Heparin plasma, and serum on the Binding Site Optilite Analyser, Jake Fisher
- P-07** Performance of a C1q Assay for use with Serum, EDTA plasma and Lithium Heparin plasma on the Binding Site Optilite Analyser, Iasmina Gavrilas
- P-08** The potent anti-inflammatory product of HMGB1 cleavage by the complement C1s, Marie Lorvellec
- P-09** Generation of Novel Antibodies Targeting the Putative Complement Regulatory Domain of CSMD1, Robert Byrne
- P-10** Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development, Martin Schmidt
- P-11** Complement dysregulation in Long COVID, Kirstie Baillie

- P-12** Roles of complement dysregulation and membrane attack complex formation in developmental synapse loss, Sarah Carpanini
- P-13** Complement in clinical trials: the search for human complement challenge models, Juliette van den Noort
- P-14** Complement receptor 1 is expressed on brain cells and impacts roles of microglia relevant to Alzheimer's disease, Nikoleta Daskoulidou
- P-15** A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop, Samuel Butler
- P-16** Differential expression of complement activation markers in the blood of individuals with clinical high-risk for psychosis, Eleftheria Kodosaki
- P-17** Utilising biomarkers to diagnose MS and predict long-term outcomes, Eleftheria Kodosaki
- P-18** Measurement of complement deposition at the neuromuscular junction in passive transfer myasthenia gravis in rats, Anja Schöttler
- P-19** Complement activation in response to hypoxia and reoxygenation in tubular epithelial cells, Saltanat Moldakhmetova
- P-20** Differentiating between activation via the lectin or the classical complement pathway in Systemic Lupus Erythematosus patients, Mads Lamm Larsen
- P-21** Safety, Tolerability and Pharmacodynamic Effects of ARO-C3, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting Complement C3, in Adult Healthy Volunteers, Hamid Moradi
- P-22** Levels of soluble complement regulators predict severity of COVID-19 symptoms, Anna Tierney
- P-23** Complement inhibitors for age-related macular degeneration (AMD): A Cochrane systematic review and meta-analysis, Nikolas Tzoumas
- P-24** Impact of C3aR on synaptic density and microglial phagocytosis, Laura Westacott